MFC adds significant information on dyspoiesis in the diagnostic work up for MDS and provides prognostic information. MNDA expression can be assessed by MFC and may facilitate evaluation of dyspoiesis when added to MDS MFC panels.
these data support the inclusion of MNDA in the diagnostic evaluation of extramedullary B-cell lymphomas particularly those in which the differential diagnosis is between low-grade follicular lymphoma and marginal zone lymphoma.
We'd like to inform you that we have updated our Privacy Notice to comply with Europe’s new General Data Protection Regulation (GDPR) that applies since 25 May 2018.